• FirefoxInstall the new Firefox »
  •  Dow Up0.19% Nasdaq Up0.57%

    Sarepta Therapeutics, Inc. (SRPT)

    13.57 Up 0.50(3.83%) Mar 27, 4:00PM EDT
    |After Hours : 13.57 0.00 (0.00%) Mar 27, 4:33PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Sarepta Therapeutics, Inc.
    215 First Street
    Suite 415
    Cambridge, MA 02142
    United States - Map
    Phone: 617-274-4000
    Website: http://www.sareptatherapeutics.com

    Index Membership:N/A
    Full Time Employees:204

    Business Summary 

    Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin. The company also focuses on developing therapeutics for the treatment of drug-resistant bacteria, Becker muscular dystrophy, progeria, adult onset pompe, lupus and graft-versus-host diseases; and other rare, genetic, anti-infective, neuromuscular, and central nervous system diseases. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Sarepta Therapeutics, Inc.

    Corporate Governance 
    Sarepta Therapeutics, Inc.’s ISS Governance QuickScore as of Mar 1, 2015 is 9. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 3; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Christopher Nishan Garabedian , 48
    Chief Exec. Officer, Pres and Director
    Mr. Sandesh Mahatme LL.M., 50
    Chief Financial Officer, Chief Accounting Officer and Sr. VP
    Dr. Jayant Aphale Ph.D., MBA, 55
    Sr. VP of Technical Operations
    Mr. David Tyronne Howton , 43
    Sr. VP, Gen. Counsel and Corp. Sec.
    Dr. Edward M. Kaye M.D., Ph.D., 66
    Chief Medical Officer and Sr. VP
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders